Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec 7;20(45):16795-810.
doi: 10.3748/wjg.v20.i45.16795.

Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis

Valerio Giannelli  1 , Vincenza Di Gregorio  1 , Valerio Iebba  1 , Michela Giusto  1 , Serena Schippa  1 , Manuela Merli  1 , Ulrich Thalheimer  1
Affiliations
Review

Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis

Valerio Giannelli et al. World J Gastroenterol. .

Abstract

Liver disease is associated with qualitative and quantitative changes in the intestinal microbiota. In cirrhotic patients the alteration in gut microbiota is characterized by an overgrowth of potentially pathogenic bacteria (i.e., gram negative species) and a decrease in autochthonous familiae. Here we summarize the available literature on the risk of gut dysbiosis in liver cirrhosis and its clinical consequences. We therefore described the features of the complex interaction between gut microbiota and cirrhotic host, the so called "gut-liver axis", with a particular attention to the acquired risk of bacterial translocation, systemic inflammation and the relationship with systemic infections in the cirrhotic patient. Such knowledge might help to develop novel and innovative strategies for the prevention and therapy of gut dysbiosis and its complication in liver cirrhosis.

Keywords: Bacterial overgrowth; Bacterial translocation; Cirrhosis; Dysbiosis; Gut; Infection; Inflammation; Lactulose; Liver; Portal hypertension; Rifaximine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Association between gut flora, systemic inflammation and the complications of cirrhosis.
See this image and copyright information in PMC

References

    1. Phillips GB, Schwartz R, Gabuzda GJ, Davidson CS. The syndrome of impending hepatic coma in patients with cirrhosis of the liver given certain nitrogenous substances. N Engl J Med. 1952;247:239–246. - PubMed
    1. Martini GA, Phear EA, Ruebner B, Sherlock S. The bacterial content of the small intestine in normal and cirrhotic subjects: relation to methionine toxicity. Clin Sci (Lond) 1957;16:35–51. - PubMed
    1. Riggio O, Varriale M, Testore GP, Di Rosa R, Di Rosa E, Merli M, Romiti A, Candiani C, Capocaccia L. Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. J Clin Gastroenterol. 1990;12:433–436. - PubMed
    1. Thomas HC, McSween RN, White RG. Role of the liver in controlling the immunogenicity of commensal bacteria in the gut. Lancet. 1973;1:1288–1291. - PubMed
    1. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303:G675–G685. - PMC - PubMed

MeSH terms